Zohoncon T M, Ouedraogo T C, Brun L V C, Obiri-Yeboah D, Djigma W F, Kabibou S, Ouattara S, Gomina M, Yonli A T, Bazie V J T E, Ouedraogo C, Lompo O, Akpona S A, Simpore J
Laboratory of Molecular Biology and Genetics (LABIOGENE), University of Ouagadougou, 03 BP 7021 Ouagadougou 03, Burkina Faso.
Teaching and Research Unit in Biochemistry and Molecular Biology, Faculty of Medicine, University of Parakou, BP 123 Parakou,Republic of Benin.
Pak J Biol Sci. 2016;19(2):49-56. doi: 10.3923/pjbs.2016.49.56.
Human papilloma virus (HPV) infection remains a worldwide concern, especially in Sub-Saharan Africa where cervical cancer is the leading cause of cancer death in women. The aim of the study was to determine the prevalence and genotypic distribution of High-Risk HPV (HR-HPV) involved in Cervical Intraepithelial Neoplasia (CIN) II and III and in cervical cancer in Parakou. Out of a total of 149 samples of cervical tissues archived, fixed and paraffin-embedded, 78 samples with histological diagnosis of CIN-II, CIN-III and cervical cancer went through deparaffinization with xylene, followed by an extraction of HPV DNA and the detection of HR-HPV by real-time multiplex PCR. The average age of the women was 40.05±13.99 years. The samples were positive to at least one HR-HPV genotype in 76.92% (50/65) of cases. The HR-HPV genotypes which are most common in the cervical cancer and in CIN-II and III were, respectively HPV-39 (38 and 37.50%), HPV-18 (35 and 31.30%), HPV-45 (35 and 31.30%), HPV-35 (9 and 25%) and HPV-52 (9 and 12.50%). The HPV-16 was absent. This study helped to detect (in samples archived, fixed and paraffin-embedded tissues) HR-HPV involved in high-grade precancerous lesions and in cervical cancer in Parakou, some of which are not covered by currently available vaccines.
人乳头瘤病毒（HPV）感染仍是一个全球性问题，尤其在撒哈拉以南非洲地区，宫颈癌是女性癌症死亡的主要原因。本研究旨在确定帕拉库地区与宫颈上皮内瘤变（CIN）II级和III级以及宫颈癌相关的高危型HPV（HR-HPV）的流行率和基因型分布。在总共149份存档、固定并石蜡包埋的宫颈组织样本中，78份经组织学诊断为CIN-II级、CIN-III级和宫颈癌的样本用二甲苯进行脱蜡，随后提取HPV DNA并通过实时多重PCR检测HR-HPV。这些女性的平均年龄为40.05±13.99岁。76.92%（50/65）的病例样本对至少一种HR-HPV基因型呈阳性。在宫颈癌以及CIN-II级和III级中最常见的HR-HPV基因型分别为HPV-39（38%和37.50%）、HPV-18（35%和31.30%）、HPV-45（35%和31.30%）、HPV-35（9%和25%）以及HPV-52（9%和12.50%）。未检测到HPV-16。本研究有助于在（存档、固定并石蜡包埋的组织样本中）检测出帕拉库地区与高级别癌前病变和宫颈癌相关的HR-HPV，其中一些未被目前可用的疫苗所覆盖。
